AmpB is a generic drug that has been in use for approximately 50 years and is considered one of the most effective agents in the treatment of systemic fungal infections. Current use of Amp B is limited as it is currently administered intravenously and has significant infusion related side effects and kidney toxicity.
Andrew Rae, iCo’s president & CEO, said: “iCo views the enormous market and compassionate use potential of a novel, oral Amphotericin drug as a win-win scenario for shareholders and our global community alike.”